Tom Creed

810 total citations
21 papers, 330 citations indexed

About

Tom Creed is a scholar working on Genetics, Epidemiology and Oncology. According to data from OpenAlex, Tom Creed has authored 21 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Epidemiology and 8 papers in Oncology. Recurrent topics in Tom Creed's work include Inflammatory Bowel Disease (14 papers), Microscopic Colitis (12 papers) and Liver Diseases and Immunity (4 papers). Tom Creed is often cited by papers focused on Inflammatory Bowel Disease (14 papers), Microscopic Colitis (12 papers) and Liver Diseases and Immunity (4 papers). Tom Creed collaborates with scholars based in United Kingdom, United States and Ireland. Tom Creed's co-authors include C Probert, Colin Dayan, Paul V. Newcomb, Richard Lee, Stephen Hearing, Morgan Moorghen, Ashwin Dhanda, Neil A. Shepherd, Bruce E. Sands and Rosemary Greenwood and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Gut.

In The Last Decade

Tom Creed

19 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Creed United Kingdom	9	190	123	79	48	41	21	330
Ángel Ponferrada Spain	9	160 0.8×	129 1.0×	80 1.0×	117 2.4×	54 1.3×	22	355
Sylwia Szymańska Poland	9	88 0.5×	113 0.9×	29 0.4×	70 1.5×	49 1.2×	40	262
Rebecca Roberts New Zealand	5	151 0.8×	57 0.5×	92 1.2×	63 1.3×	58 1.4×	7	313
Sylvie Scharl Switzerland	10	179 0.9×	158 1.3×	130 1.6×	90 1.9×	219 5.3×	15	514
Heba Iskandar United States	8	208 1.1×	158 1.3×	50 0.6×	101 2.1×	67 1.6×	20	399
Efthymios P. Tsounis Greece	9	51 0.3×	83 0.7×	37 0.5×	30 0.6×	70 1.7×	22	245
M. Farbstein Israel	5	196 1.0×	134 1.1×	33 0.4×	101 2.1×	69 1.7×	10	412
Alessandro Adriani Italy	10	93 0.5×	105 0.9×	139 1.8×	119 2.5×	40 1.0×	16	425
Renu Singh India	12	102 0.5×	61 0.5×	39 0.5×	89 1.9×	121 3.0×	56	448
M. Besnard France	9	130 0.7×	90 0.7×	30 0.4×	119 2.5×	82 2.0×	21	299

Countries citing papers authored by Tom Creed

Since Specialization

Citations

This map shows the geographic impact of Tom Creed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Creed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Creed more than expected).

Fields of papers citing papers by Tom Creed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Creed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Creed. The network helps show where Tom Creed may publish in the future.

Co-authorship network of co-authors of Tom Creed

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Creed. A scholar is included among the top collaborators of Tom Creed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Creed. Tom Creed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parkes, Gareth, Ayesha Akbar, Ian Beales, et al.. (2025). Health-related quality of life outcomes among vedolizumab-treated patients with inflammatory bowel disease in the UK and Ireland: a 52-week observational study (OCTAVO). Journal of Patient-Reported Outcomes. 9(1). 80–80.

Collard, T J, et al.. (2021). 5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. British Journal of Cancer. 124(12). 1959–1969. 10 indexed citations

Parkes, Gareth, Ian Beales, Martin Buckley, et al.. (2020). P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2. Journal of Crohn s and Colitis. 14(Supplement_1). S575–S576. 2 indexed citations

Metcalfe, Chris, et al.. (2016). Does education influence the acceptability of faecal microbiota transplantation in colitis: A cross-sectional study. Cogent Medicine. 3(1). 1233685–1233685. 3 indexed citations

Heap, Graham, Abhinav Singh, Claire Bewshea, et al.. (2014). OC-004 Thiopurine Induced Pancreatitis In Inflammatory Bowel Disease: Clinical Features And Genetic Determinants. Gut. 63(Suppl 1). A2.2–A3. 2 indexed citations

Dhanda, Ashwin, Tom Creed, Rosemary Greenwood, Bruce E. Sands, & C Probert. (2012). Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?. Inflammatory Bowel Diseases. 18(11). 2056–2062. 32 indexed citations

Sands, Bruce E., William J. Sandborn, Tom Creed, et al.. (2012). Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis. Gastroenterology. 143(2). 356–364.e1. 26 indexed citations

Dhanda, Ashwin, Rosemary Greenwood, Tom Creed, & C Probert. (2011). Endoscopy can be avoided in the assessment of ulcerative colitis in clinical trials. Gut. 60(Suppl 1). A140.3–A141. 1 indexed citations

Dhanda, Ashwin, Tom Creed, Rosemary Greenwood, Bruce E. Sands, & C Probert. (2011). Can Endoscopy Be Avoided in the Assessment of Ulcerative Colitis in Clinical Trials?. Gastroenterology. 140(5). S–420.

10.

Greenwood, Rosemary, et al.. (2010). Mortality in ulcerative colitis—what should we tell our patients? Three year mortality following admission for the treatment of ulcerative colitis: a 6 year retrospective case review. Frontline Gastroenterology. 1(1). 35–41. 4 indexed citations

11.

Christmas, David, Abdulla A.‐B. Badawy, Dana Hince, et al.. (2010). Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. Nutrition Research. 30(10). 678–688. 37 indexed citations

12.

Creed, Tom, et al.. (2009). The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone. The Journal of Immunology. 183(1). 164–171. 61 indexed citations

13.

Tobias, Jonathan H., Tom Creed, A.J. Bell, et al.. (2009). Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease. Osteoporosis International. 21(3). 507–513. 8 indexed citations

14.

Probert, C, et al.. (2009). P291 - IL-2 enhances the in vitro proliferation of T cells from patients with IBD but does not influence in vitro steroid resistance. Journal of Crohn s and Colitis. 3(1). S125–S125. 1 indexed citations

15.

Sands, Bruce E., William J. Sandborn, Tom Creed, et al.. (2009). 389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis. Gastroenterology. 136(5). A–65. 2 indexed citations

16.

Creed, Tom, et al.. (2009). Current Practices for Assessing Colonoscopy Bowel Preparation in the U.K. Gastrointestinal Endoscopy. 69(5). AB219–AB219. 2 indexed citations

17.

Creed, Tom & C Probert. (2007). Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies. Alimentary Pharmacology & Therapeutics. 25(2). 111–122. 46 indexed citations

18.

Creed, Tom, C Probert, Morgan Moorghen, et al.. (2006). Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease. Alimentary Pharmacology & Therapeutics. 23(10). 1435–1442. 70 indexed citations

19.

Creed, Tom, et al.. (2004). Should we monitor vitamin B 12 levels in patients who have had end-ileostomy for inflammatory bowel disease?. International Journal of Colorectal Disease. 19(4). 316–318. 8 indexed citations

20.

Creed, Tom, et al.. (2003). Basiliximab (IL-2 receptor antagonist) as a steroid sensistising agent in steroid resistant ulcerative colitis. Gastroenterology. 124(4). A7–A7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact